"10.1371_journal.pone.0128151","plos one","2015-06-01T00:00:00Z","Drew C Deniger; Jianqiang Yu; M Helen Huls; Matthew J Figliola; Tiejuan Mi; Sourindra N Maiti; George F Widhopf; Lenka V Hurton; Radhika Thokala; Harjeet Singh; Simon Olivares; Richard E Champlin; William G Wierda; Thomas J Kipps; Laurence J N Cooper","Pediatrics, Childrens Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America; Medicine, Moores Cancer Center, University of California San Diego, San Diego, California, United States of America; Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America","Conceived and designed the experiments: DCD REC WGW TJK LJNC. Performed the experiments: DCD JY MHH MJF TM SNM GFW RT. Analyzed the data: DCD MHH MJF TM JY GFW. Contributed reagents/materials/analysis tools: DCD JY LVH GFW HS SO WGW TJK. Wrote the paper: DCD WGW TKJ LJNC.","Dr. Cooper founded and owns InCellerate, Inc. He has patents with Sangamo BioSciences with artificial nucleases. He consults with Targazyme, Inc. (formerly American Stem cells, Inc.), GE Healthcare, Ferring Pharmaceuticals, Fate Therapeutics, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He is on the Scientific Advisory Board of Cellectis. He receives honoraria from Miltenyi Biotec. This does not alter the authors adherence to all PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","06","Drew C Deniger","DCD",15,TRUE,5,8,6,4,TRUE,TRUE,FALSE,0,NA,FALSE
